Safety Study of SGN-CD70A in Cancer Patients

NCT02216890 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

38

Enrollment

INDUSTRY

Sponsor class

Conditions

Renal Cell Carcinoma
Mantle-Cell Lymphoma
Diffuse, Large B-Cell, Lymphoma
Follicular Lymphoma, Grade 3

Interventions

DRUG: SGN-CD70A

Sponsor

Seagen Inc.